These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22342915)

  • 1. HIV-derived vectors for therapy and vaccination against HIV.
    Di Nunzio F; Félix T; Arhel NJ; Nisole S; Charneau P; Beignon AS
    Vaccine; 2012 Mar; 30(15):2499-509. PubMed ID: 22342915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
    Chang LJ; Liu X; He J
    Gene Ther; 2005 Jul; 12(14):1133-44. PubMed ID: 15750613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel trans-lentiviral vector that affords predictable safety.
    Wu X; Wakefield JK; Liu H; Xiao H; Kralovics R; Prchal JT; Kappes JC
    Mol Ther; 2000 Jul; 2(1):47-55. PubMed ID: 10899827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral vectors for HIV disease prevention and treatment.
    Lemiale F; Korokhov N
    Vaccine; 2009 May; 27(25-26):3443-9. PubMed ID: 19201386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication.
    Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J
    Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retroviral vectors for gene therapy of AIDS and cancer.
    Chang LJ; He J
    Curr Opin Mol Ther; 2001 Oct; 3(5):468-75. PubMed ID: 11699891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of HIV as a gene transfer vector.
    Pluta K; Kacprzak MM
    Acta Biochim Pol; 2009; 56(4):531-95. PubMed ID: 19936329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
    Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
    Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
    Mautino MR; Keiser N; Morgan RA
    J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
    Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
    Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
    Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
    Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
    Wingard JB; Anderson B; Weissman D
    Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
    Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
    Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.
    Bell AJ; Fegen D; Ward M; Bank A
    Exp Biol Med (Maywood); 2010 Oct; 235(10):1269-76. PubMed ID: 20876083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV gene therapy using RNA virus systems.
    Hayafune M; Miyano-Kurosaki N; Kusunoki A; Mouri Y; Takaku H
    Nucleic Acids Symp Ser (Oxf); 2006; (50):79-80. PubMed ID: 17150826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications.
    Romano G; Claudio PP; Tonini T; Giordano A
    Eur J Dermatol; 2003; 13(5):424-9. PubMed ID: 14693483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of HIV-1 with RNA interference: a multiple shRNA approach.
    ter Brake O; Konstantinova P; Ceylan M; Berkhout B
    Mol Ther; 2006 Dec; 14(6):883-92. PubMed ID: 16959541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.